Drug Trial Radar · NCT04314531
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
296
Actual
Start
Jul 1, 2020
Primary completion
Jun 4, 2025
Study completion Apr 2026
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
Conditions
- Active Psoriatic Arthritis
Interventions
TILDDrug
one 1 mL injection of study medication
matching placebo injectionsDrug
one 1 mL injection of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who achieve American College of Rheumatology [ACR20]Time frame: at Week 24
Locations
49 sites in 9 countries. Site status is shown where the registry gives one.
Sunpharma site no. 12
Covina, California
Sunpharma site no. 04
Miami Beach, Florida
Sunpharma site no. 02
New Port Richey, Florida
Sunpharma site no. 07
Tamarac, Florida
Sunpharma site no. 05
Springfield, Missouri
Sunpharma site no. 10
Lincoln, Nebraska
Sunpharma site no. 11
Greenville, South Carolina
Sunpharma site no. 09
Lubbock, Texas
Sunpharma site no. 03
San Antonio, Texas
Sunpharma site no. 01
Tomball, Texas
Sunpharma site no. 06
Spokane, Washington
Sunpharma Site 39
Phillip, Australian Capital Territory, Australia
Sunpharma site no. 08
Hobart, Tasmania, Australia
Sunpharma Site 64
Brno, Czechia
Sunpharma Site 97
Prague, Czechia
Sunpharma Site 63
Zlín, Czechia
Sunpharma Site 73
Berlin, Germany
Sunpharma Site 92
Herne, Germany
Sunpharma Site 113
Kochi, India
Sunpharma Site 111
Surat, Gujarat, India
Sunpharma Site 110
Bangalore, Karnataka, India
Sunpharma Site 107
Belagavi, Karnataka, India
Sunpharma Site 109
Hubli, Karnataka, India
Sunpharma Site 108
Pune, Maharashtra, India
Sunpharma Site 112
Hyderabad, Telangana, India
Sunpharma Site 106
Lucknow, Uttar Pradesh, India
Sunpharma Site 22
Kitakyushu-shi, Japan
Sunpharma Site 88
Kumamoto, Japan
Sunpharma Site 87
Osaka, Japan
Sunpharma Site 23
Tsu, Japan
Sunpharma Site 84
Nagoya, Aichi-ken, Japan
Sunpharma Site 89
Kitakyushu, Fukuoka, Japan
Sunpharma Site 86
Sendai, Miyagi, Japan
Sunpharma Site 24
Miyazaki, Miyazaki, Japan
Sunpharma Site 91
Mitaka, Tokyo, Japan
Sunpharma Site 85
Shinjuku, Tokyo, Japan
Sunpharma Site 90
tabashi City, Tokyo, Japan
Sunpharma Site 93
Bialystok, Poland
Sunpharma Site 95
Bialystok, Poland
Sunpharma Site 94
Lublin, Poland
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.